The comparison of the therapeutic effects between 0.05% Tsporin and 0.05% Restasis in meibomian gland dysfunction

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0006070

Enrollment

Registered

2021-04-07

Start date

2016-08-30

Completion date

Unknown

Last updated

2021-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Ocular surface disease index (OSDI), meibomian gland dysfunction grading, corneal staining, tear film destruction time (TBUT), and tear secretion between Tsporin and restasis groups at 12 weeks

Fluorometholone) was used 4 times a day for the initial 4 weeks of treatment for improving initial discomfort and drug compliance in all patients, and then randomly assigned to the Tsporin and Restasi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria -Adults over 19 years of age -Patients diagnosed with meibomian gland dysfunction -Patients with tear film destruction time of 8 seconds or less -Patients who complain of one or more of the following symptoms related to tear film instability (foreign body sensation, glare, tears)

Exclusion criteria

Exclusion criteria: Exclusion criteria -Patients being treated with anti-inflammatory therapy for dry eye syndrome, such as steroid eye drops or non-steroidal anti-inflammatory eye drops -Patients taking systemic steroids and immunosuppressants -Patients with a history of ocular surgery within the last 6 months -Patients who wear contact lenses during the clinical study -Pregnant and lactating women -Patients with a history of using cyclosporine eyedrops within the last 2 weeks -Those whose intraocular pressure exceeds 25mmHg -Punctal occlusion was performed within the last 1 month or during the clinical trial participation period -Hypersensitivity reaction or suspicion of hypersensitivity to the ingredients of the clinical trial drug -When the researcher determines that participation is inappropriate -Patients with active ocular infection

Design outcomes

Secondary

Measure	Time frame
Tear-film break up time;Grading of meibomian gland dysfunction	—

Primary

Measure	Time frame
OSDI score	—

Countries

Korea, Republic of

Contacts

Public ContactDong Hyun Kim

Gachon University Gil Medical Center

amidfree@gmail.com+82-32-460-3364

Outcome results